JP2017526689A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526689A5
JP2017526689A5 JP2017511914A JP2017511914A JP2017526689A5 JP 2017526689 A5 JP2017526689 A5 JP 2017526689A5 JP 2017511914 A JP2017511914 A JP 2017511914A JP 2017511914 A JP2017511914 A JP 2017511914A JP 2017526689 A5 JP2017526689 A5 JP 2017526689A5
Authority
JP
Japan
Prior art keywords
dengue
composition
virus
use according
serotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017511914A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526689A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/070060 external-priority patent/WO2016034629A1/en
Publication of JP2017526689A publication Critical patent/JP2017526689A/ja
Publication of JP2017526689A5 publication Critical patent/JP2017526689A5/ja
Pending legal-status Critical Current

Links

JP2017511914A 2014-09-02 2015-09-02 デング熱ウイルス病に対するワクチン組成物 Pending JP2017526689A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14306350.1 2014-09-02
EP14306350 2014-09-02
EP15305851 2015-06-04
EP15305851.6 2015-06-04
PCT/EP2015/070060 WO2016034629A1 (en) 2014-09-02 2015-09-02 Vaccine compositions against dengue virus diseases

Publications (2)

Publication Number Publication Date
JP2017526689A JP2017526689A (ja) 2017-09-14
JP2017526689A5 true JP2017526689A5 (cg-RX-API-DMAC7.html) 2018-10-11

Family

ID=54064325

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017511914A Pending JP2017526689A (ja) 2014-09-02 2015-09-02 デング熱ウイルス病に対するワクチン組成物

Country Status (14)

Country Link
US (1) US10946087B2 (cg-RX-API-DMAC7.html)
EP (1) EP3188751A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017526689A (cg-RX-API-DMAC7.html)
KR (2) KR20230170812A (cg-RX-API-DMAC7.html)
CN (1) CN106999564A (cg-RX-API-DMAC7.html)
AU (1) AU2015310951A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017004197A2 (cg-RX-API-DMAC7.html)
CA (1) CA2958949A1 (cg-RX-API-DMAC7.html)
MX (1) MX2017002794A (cg-RX-API-DMAC7.html)
MY (1) MY192739A (cg-RX-API-DMAC7.html)
PH (1) PH12017500304A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201701256RA (cg-RX-API-DMAC7.html)
TW (1) TWI852899B (cg-RX-API-DMAC7.html)
WO (1) WO2016034629A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3539565T3 (fi) 2013-03-15 2023-04-19 Takeda Vaccines Inc Koostumuksia ja menetelmiä dengue-viruksen kimeerisille rakenteille rokotteissa
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
CN120392993A (zh) * 2016-04-13 2025-08-01 武田疫苗股份有限公司 在儿童和年轻人中针对登革热病毒接种疫苗的组合物和方法
US11531029B2 (en) 2017-05-08 2022-12-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and compositions for the detection of flavivirus infections
SG11202002933TA (en) 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
KR20210071979A (ko) 2018-09-05 2021-06-16 다케다 백신즈 인코포레이티드 뎅기열 백신 단위 용량 및 이의 투여
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
AU2020331884B2 (en) * 2019-08-16 2025-01-23 Takeda Vaccines, Inc. Methods for preventing dengue and Hepatitis A
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741077B1 (fr) * 1995-11-14 1998-01-23 Pasteur Institut Vaccin polyvalent anti-dengue
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
DK1625852T3 (da) 1997-02-28 2010-09-20 Sanofi Pasteur Biologics Co Kimæriske flavivirusvacciner
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
AU1813901A (en) 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
DK2278012T3 (en) 2000-02-16 2015-12-07 Us Government Immunogenic dengue 2 virus chimeras
WO2002102828A2 (en) 2001-06-01 2002-12-27 Acambis, Inc. Chimeric flavivirus vectors
MXPA04006870A (es) 2002-01-15 2005-05-16 Acambis Inc Vacunas para flavivirus.
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
AU2003239932A1 (en) 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
BRPI0613328A2 (pt) 2005-06-17 2011-01-04 Sanofi Pasteur cepa do vìrus da dengue-1 vivo atenuado, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada e fragmento de poliproteìna
EP1891210B1 (en) 2005-06-17 2010-07-28 Sanofi Pasteur Dengue serotype 2 attenuated strain
KR101357685B1 (ko) 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
US7968102B2 (en) 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
US8591916B2 (en) 2007-01-31 2013-11-26 Sanofi Pasteur Biologics, Llc Flavivirus vaccine vector against influenza virus
US8715689B2 (en) 2008-04-30 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric west nile/dengue viruses
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
KR20140015127A (ko) 2009-07-29 2014-02-06 베른드 헬무트 아담 렘 폴리머 입자 및 이의 용도
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
EP2571990A4 (en) 2010-05-21 2013-11-20 Univ Pittsburgh UNIVERSAL SEQUENCES OF DENGUE VIRUS AND METHODS OF USE
WO2012051491A1 (en) 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
ITMI20121231A1 (it) * 2012-07-16 2014-01-17 St Microelectronics Srl Metodo di controllo burst-mode per basso consumo in ingresso in convertitori risonanti e relativo dispositivo di controllo
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
MX2015000446A (es) 2012-07-24 2015-03-12 Sanofi Pasteur Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue.
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
WO2017005654A1 (en) * 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination.

Similar Documents

Publication Publication Date Title
JP2017526689A5 (cg-RX-API-DMAC7.html)
JP2015524421A5 (cg-RX-API-DMAC7.html)
Yong et al. Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus
JP2019151636A5 (cg-RX-API-DMAC7.html)
JP2015524422A5 (cg-RX-API-DMAC7.html)
Modjarrad MERS-CoV vaccine candidates in development: The current landscape
RU2017113571A (ru) Рекомбинантные вакцины от fmdv и их применение
HK1246658A1 (zh) 猪流行性腹泻病毒品种及其免疫原性组合物
MX352478B (es) Proteina vp6 de la capside de norovirus y rotavirus para el uso como vacuna combinada.
JP2016508999A5 (cg-RX-API-DMAC7.html)
JP2017502662A5 (cg-RX-API-DMAC7.html)
WO2017156511A8 (en) Live attenuated zika virus vaccine
Pripuzova et al. Exploring of primate models of tick-borne flaviviruses infection for evaluation of vaccines and drugs efficacy
WO2013001285A3 (en) Fmdv vp1 peptides
JP2013523783A5 (cg-RX-API-DMAC7.html)
JP2019511221A5 (cg-RX-API-DMAC7.html)
JP2016504315A5 (cg-RX-API-DMAC7.html)
JP2018500878A5 (cg-RX-API-DMAC7.html)
CO6541529A2 (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos
MX2022000718A (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9.
JP2016528176A5 (cg-RX-API-DMAC7.html)
WO2014140166A3 (en) Vaccine
Zhang et al. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
Kim et al. Cross-protective immune responses elicited by a Korean variant of infectious bronchitis virus